Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Atezolizumab Combo Demonstrates Survival Benefit for ES-SCLC in Maintenance Phase

January 31st 2021

January 31, 2021 - The latest data from the IMpower133 trial shows that maintenance therapy with atezolizumab plus carboplatin and etoposide improves overall survival and progression-free survival for patients with extensive stage small cell lung cancer.

Updated Data Show Durable Response for Tepotinib in MET exon 14 Skipping NSCLC

January 31st 2021

Tepotinib demonstrated durable clinical activity in patients with MET exon 14 skipping non‒small cell lung cancer.

Dr. Cho on the Updated Efficacy of Repotrectinib in TKI-Naïve ROS1+ NSCLC

January 31st 2021

Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.

Dr. Reck on the Efficacy of Maintenance Atezolizumab in ES-SCLC

January 31st 2021

Martin Reck, MD, PhD, discusses the efficacy of maintenance atezolizumab in patients with extensive-stage small cell lung cancer.

Neoadjuvant Atezolizumab Elicits Impressive Responses in Resectable NSCLC

January 30th 2021

January 30, 2021 - Neoadjuvant atezolizumab followed by surgery resulted in a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, as well as significant surgical outcomes with a high rate of R0 resection.

CONFIRM Data Push Nivolumab into Treatment Landscape for Relapsed Mesothelioma

January 30th 2021

January 30, 2021 - Data from the phase 3 CONFIRM trial support single-agent nivolumab as an effective treatment approach for patients with previously treated malignant mesothelioma.

Dr. Liu on Emerging Data With Novel ADCs in NSCLC

January 30th 2021

Stephen Liu, MD, discusses emerging research on antibody–drug conjugate in non–small cell lung cancer that were presented during the 2020 World Conference on Lung Cancer.

Dr. Velcheti on the Results of the CodeBreaK 100 Primary Analysis in KRAS G12C+ NSCLC

January 30th 2021

Vamsidhar Velcheti, MD, discusses the results from the primary analysis of the CodeBreaK 100, which examined sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

HRQoL Maintained With Adjuvant Osimertinib in EGFR+ NSCLC

January 30th 2021

January 29, 2021 - Health-related quality of life was maintained for patients with EGFR-positive non–small cell lung cancer who received treatment with adjuvant osimertinib versus placebo, with no clinically meaningful differences noted between study arms.

Pembrolizumab/Ipilimumab Combo Does Not Improve Survival, Shows Higher Toxicity in PD-L1+ NSCLC

January 30th 2021

January 29, 2021 - Pembrolizumab plus ipilimumab did not improve survival and had higher rates of toxicity versus pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer who had a PD-L1 tumor proportion score of 50% or greater, and did not harbor EGFR or ALK aberrations.

Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC

January 30th 2021

January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.

Datopotamab Deruxtecan Elicits Early Antitumor Activity in Relapsed/Refractory Metastatic NSCLC

January 29th 2021

January 29, 2021 - The investigational antibody-drug conjugate datopotamab deruxtecan demonstrated encouraging antitumor activity and a manageable safety profile in patients with advanced or metastatic non–small cell lung cancer.

Patritumab Deruxtecan Displays Promising Efficacy in EGFR-Mutant NSCLC

January 29th 2021

January 29, 2021 - The HER3-directed antibody-drug conjugate patritumab deruxtecan continued to demonstrate clinically meaningful antitumor activity and a manageable safety profile at the recommended expansion dose of 5.6 mg/kg in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer.

COVID-19 Pandemic Has Led to Decrease in Lung Cancer Diagnoses and Increase in Mortality Rate, Study Shows

January 29th 2021

January 29, 2021 - Thirty percent fewer new lung cancer cases have been diagnosed during the coronavirus disease 2019 pandemic versus pre-pandemic, with more symptomatic and severe cases of non–small cell lung cancer diagnosed during this period.

Adjuvant Osimertinib Extends DFS Irrespective of Prior Adjuvant Chemo in EGFR+ NSCLC

January 29th 2021

January 29, 2021 - Adjuvant osimertinib was found to improve disease-free survival in patients with EGFR-mutated non–small cell lung cancer, irrespective of previous adjuvant chemotherapy received or disease stage.

Trastuzumab Deruxtecan Shows Antitumor Activity in HER2-Overexpressing NSCLC

January 29th 2021

January 29, 2021 - The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki demonstrated antitumor activity in patients with HER2-overexpressing non–small cell lung cancer, irrespective of expression levels.

Nab-Paclitaxel Noninferior to Docetaxel in Previously Treated NSCLC

January 29th 2021

January 29, 2021 - Nab-paclitaxel proved to be noninferior to docetaxel, having showcased improved progression-free survival, overall survival, and overall response rate in patients with previously treated advanced non–small cell lung cancer.

Dr. Majem on Patient-Reported Outcomes With Osimertinib in EGFR+ NSCLC

January 29th 2021

Margarita Majem, MD, PhD, discusses the patient-reported outcomes with osimertinib in EGFR-mutated non–small cell lung cancer from the pivotal phase 3 ADAURA trial.

Pembrolizumab Plus Chemoradiation Therapy Yields Promising Results for Patients with Unresectable, Locally Advanced NSCLC

January 29th 2021

January 29, 2021 - The combination of pembrolizumab plus concurrent chemoradiation therapy showed antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer, regardless of PD-L1 status or tumor histology.

Amivantamab Shows Encouraging Activity in EGFR Exon 20–Positive NSCLC

January 29th 2021

January 29, 2021 - Amivantamab elicited high and sustained responses in pretreated patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.